论文信息 - HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration. - 字舞流文

HAWK and HARRIER: 96-Week outcomes from the phase 3 trials of brolucizumab for neovascular age-related macular degeneration.

Rishi P. Singh | U. Schmidt-Erfurth | A. Koh | Y. Ogura | R. Tadayoni | F. Holz | G. Jaffe | P. Dugel | G. Weissgerber | K. Gedif